Legend Biotech (LEGN) Q2 2026 Earnings Call Transcript
Legend Biotech (LEGN) reported Q2 2026 results on an earnings call. Worldwide CARVYKTI net trade sales were $657M (+50% YoY), with U.S. $472M (+32%) and ex-U.S. $185M (+128%). Total revenue was $387.5M (+52%), adjusted net income $63.1M ($0.16/share), and cash $965M. Q3 gross margin guidance was lower-50% range.
How this was made
The 30-second read
Why it matters
Traders can update near-term expectations using the explicit Q3 gross-margin range and the disclosed drivers of Q2 operating leverage, cash build, and outpatient/community treatment mix.
Market read
The call combines strong CARVYKTI growth and profitability with a specific sequential gross-margin headwind for Q3, making it actionable for earnings-model and margin-sensitivity positioning.
What to watch
Tax expense includes the expected impact of a pending China advance pricing agreement, which may create earnings volatility independent of core operating performance.
Background
Legend Biotech held its Q2 2026 earnings call with interim CEO Alan Bash and CFO Carlos Santos, covering CARVYKTI commercial performance, profitability, cash, and early clinical updates.
Ticker impact
Legend Biotech reported Q2 2026 results and guided Q3 gross margin on net product sales to the lower 50% range.
Near-term volatility likely around the Q3 gross-margin guide, partially offset by strong CARVYKTI net trade sales growth and profitability improvement.
Multiple new, company-specific datapoints are disclosed: Q2 revenue, adjusted net income, cash position, and explicit Q3 margin guidance, which can drive earnings-model revisions even without a full consensus comparison in the text.
Market effects
CAR-T commercial trajectory and margin trajectory signals for other oncology cell therapy developers, especially around manufacturing utilization and outpatient mix.
International revenue growth and FX sensitivity are highlighted as a reporting and risk factor for global biotech investors.
China tax APA impact and multi-market launch uptake underscore cross-border regulatory and operational execution risks for global biopharma.
Counterpoint
The Q3 gross margin guide to the lower 50% range could indicate broader cost or pricing pressure that may persist beyond one quarter, despite strong CARVYKTI sales growth.
Key entities
- companyLegend Biotech
NASDAQ-listed cell therapy company reporting Q2 2026 results and providing Q3 gross-margin guidance plus clinical and platform updates.
- productCARVYKTI (cilta-cel)
Lead approved CAR-T therapy whose net trade sales growth and line adoption were central to the quarter’s results.
- clinical_programLB2501
In vivo CAR-T program with Phase I response data cited in the call takeaways.
- clinical_programLB2102
In vivo CAR-T program with Phase I data cited in the call takeaways.
